These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 31050099

  • 1. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
    Zhou FL, Watada H, Tajima Y, Berthelot M, Kang D, Esnault C, Shuto Y, Maegawa H, Koya D.
    Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
    [Abstract] [Full Text] [Related]

  • 2. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
    Shao SC, Chang KC, Lin SJ, Chien RN, Hung MJ, Chan YY, Kao Yang YH, Lai EC.
    Cardiovasc Diabetol; 2020 Feb 12; 19(1):17. PubMed ID: 32050968
    [Abstract] [Full Text] [Related]

  • 3. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
    Dennis JM, Young KG, McGovern AP, Mateen BA, Vollmer SJ, Simpson MD, Henley WE, Holman RR, Sattar N, Pearson ER, Hattersley AT, Jones AG, Shields BM, MASTERMIND consortium.
    Lancet Digit Health; 2022 Dec 12; 4(12):e873-e883. PubMed ID: 36427949
    [Abstract] [Full Text] [Related]

  • 4. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
    Cahn A, Melzer-Cohen C, Pollack R, Chodick G, Shalev V.
    Diabetes Obes Metab; 2019 Feb 12; 21(2):340-348. PubMed ID: 30207040
    [Abstract] [Full Text] [Related]

  • 5. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M, Peng X, Geremakis C, Bae J.
    J Manag Care Spec Pharm; 2015 Dec 12; 21(12):1204-12. PubMed ID: 26679969
    [Abstract] [Full Text] [Related]

  • 6. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I, Zhang R, Mamza JB, Ford M, Morris T, Banerjee A, Khunti K.
    Diabetes Obes Metab; 2022 Nov 12; 24(11):2138-2147. PubMed ID: 35676798
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
    Cha SA, Park YM, Yun JS, Lim TS, Song KH, Yoo KD, Ahn YB, Ko SH.
    Lipids Health Dis; 2017 Apr 13; 16(1):58. PubMed ID: 28403877
    [Abstract] [Full Text] [Related]

  • 9. Comparative effects of sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors on kidney function decline in Japanese individuals with type 2 diabetes.
    Yoshida N, Hanai K, Babazono T.
    Clin Exp Nephrol; 2024 Sep 13; 28(9):894-901. PubMed ID: 38613740
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study.
    Ng PY, Ng AK, Ip A, Wu MZ, Guo R, Yiu KH.
    Crit Care Med; 2023 Aug 01; 51(8):1074-1085. PubMed ID: 37026864
    [Abstract] [Full Text] [Related]

  • 12. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T, Iwasaki K, Maedera S, Ito K, Takeshima T, Noma H, Shojima N.
    Curr Med Res Opin; 2020 Mar 01; 36(3):403-409. PubMed ID: 31855074
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study.
    Yu OHY, Dell'Aniello S, Shah BR, Brunetti VC, Daigle JM, Fralick M, Douros A, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ronksley PE, Filion KB, Ernst P, Lix LM, Canadian Network for Observational Drug Effect Studies (CNODES) Investigators.
    Diabetes Care; 2020 Oct 01; 43(10):2444-2452. PubMed ID: 32759360
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH, Fryer AA, Anderson SG, Livingston M, Lunt M, Davies M, Moreno GYC, Gadsby R, Young RJ, Stedman M.
    Diabetes Obes Metab; 2018 Jul 01; 20(7):1659-1669. PubMed ID: 29516618
    [Abstract] [Full Text] [Related]

  • 19. Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
    Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H.
    Diabetes Obes Metab; 2020 Mar 01; 22(3):458-462. PubMed ID: 31486230
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.